Astec Lifesciences Limited (ASTEC) AI Stock Analysis

• Market Cap: ₹18.75B
• Dividend Yield: N/A
• Average Volume (3M): 364.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: 1.54%
• EPS Growth: -8.04%
• Country: IN
• Employees: 606
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): -8.70
• Shares Outstanding: 22,281,660
• 10 Day Avg. Volume: 1,087,843
• 30 Day Avg. Volume: 364,669
• PEG Ratio: -0.06
• Price to Book (P/B): 6.10
• Price to Sales (P/S): 3.76
• P/FCF Ratio: -47.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 2,740.92
• Revenue Forecast (FY): ₹735.35B

• Rating: 46 Neutral
• Price Target: ₹871.00 ▲(23.81% Upside)

Astec Lifesciences Limited's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, profitability issues, and liquidity constraints. While technical analysis shows some bullish momentum, overbought conditions pose a risk. The negative P/E ratio and lack of dividend yield further detract from the stock's attractiveness.

Positive Factors

R&D Capabilities

Astec's emphasis on R&D enables it to innovate in agrochemicals and pharmaceuticals, supporting long-term growth and market competitiveness.

Market Reach

Strategic partnerships expand Astec's distribution network, increasing its global footprint and potential revenue streams.

Product Diversity

A diverse product portfolio in agrochemicals and pharmaceuticals reduces dependency on a single market, enhancing resilience.

Negative Factors

Declining Revenue

Persistent revenue decline indicates potential market share loss or operational inefficiencies, impacting long-term financial health.

High Leverage

High leverage increases financial risk and limits flexibility, potentially affecting the company's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow highlights liquidity issues, raising concerns about the company's ability to sustain operations without external funding.

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec Lifesciences Limited (ASTEC) is a leading manufacturer and supplier of agrochemicals and pharmaceutical intermediates based in India. The company operates primarily in the agrochemical sector, focusing on the production of herbicides, fungicides, insecticides, and other crop protection products. Additionally, ASTEC is involved in the development of pharmaceutical intermediates and specialty chemicals, catering to both domestic and international markets. Leveraging its strong research and development capabilities, the company aims to provide innovative solutions for sustainable agriculture and healthcare.

How the Company Makes Money

Astec Lifesciences generates revenue primarily through the sale of its agrochemical products and pharmaceutical intermediates. The company's revenue model is built on manufacturing and distributing a diverse range of crop protection chemicals, which are sold to agricultural businesses and distributors. Key revenue streams include the sale of branded and generic agrochemicals, contract manufacturing services for third parties, and the export of products to international markets. Significant partnerships with global agricultural firms enhance its market reach and contribute to earnings through collaborative projects and joint ventures. Additionally, the company's focus on research and development allows it to introduce new products, thereby expanding its market presence and driving revenue growth.

Astec Lifesciences Limited Financial Statement Overview

Summary

Astec Lifesciences Limited faces significant financial challenges. The income statement highlights declining revenue and profitability, with negative margins impacting overall performance. The balance sheet shows high leverage and decreasing equity ratios, increasing financial risk. Cash flow difficulties, marked by negative free cash flow, further exacerbate the situation, suggesting liquidity constraints and a need for strategic financial management.

Income Statement

The income statement shows a decline in revenue from 2023 to 2025, with a significant drop in gross profit and net income, resulting in negative margins. The company has experienced negative net profit margins in the most recent years, indicating profitability issues. The revenue growth has been negative, reflecting a challenging market environment or operational difficulties.

Balance Sheet

The balance sheet indicates high leverage with an increasing debt-to-equity ratio over the years, reflecting financial risk. The equity ratio has also decreased, signaling reduced asset backing by equity. Although the company maintains a positive stockholder's equity, the increasing liabilities pose a risk to financial stability.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow in recent years, highlighting liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating a struggle to convert income into cash. Consistently negative free cash flow growth raises concerns about the company’s ability to sustain operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.03B	3.81B	4.58B	6.28B	6.77B	5.55B
Gross Profit	973.81M	-685.16M	1.33B	2.27B	2.86B	2.10B
EBITDA	-271.65M	-662.07M	-2.69M	893.14M	1.65B	1.19B
Net Income	-1.28B	-1.35B	-469.30M	255.65M	898.59M	650.49M
Balance Sheet
Total Assets	0.00	8.81B	9.75B	9.79B	8.97B	6.78B
Cash, Cash Equivalents and Short-Term Investments	5.75M	8.55M	16.47M	27.54M	33.44M	15.42M
Total Debt	0.00	5.55B	4.94B	3.41B	2.79B	1.87B
Total Liabilities	-2.35B	6.46B	6.05B	5.60B	5.00B	3.68B
Stockholders Equity	2.35B	2.35B	3.69B	4.19B	3.96B	3.09B
Cash Flow
Free Cash Flow	0.00	-302.20M	-1.25B	-426.03M	-803.74M	-1.11B
Operating Cash Flow	0.00	-83.99M	102.21M	746.56M	236.04M	-81.62M
Investing Cash Flow	0.00	-152.30M	-1.35B	-1.13B	-1.04B	-731.10M
Financing Cash Flow	0.00	237.33M	1.25B	377.70M	804.77M	813.36M

Astec Lifesciences Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 703.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Positive. The current price of 703.5 is below the 20-day moving average (MA) of 703.75, below the 50-day MA of 742.62, and below the 200-day MA of 775.55, indicating a bullish trend. The MACD of 40.14 indicates Negative momentum. The RSI at 66.02 is Neutral, neither overbought nor oversold. The STOCH value of 85.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PUNJABCHEM	64 Neutral	₹16.00B	30.60	―	0.23%	10.70%	32.65%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹26.90B	23.22	―	0.89%	5.74%	16.06%
IGPL	59 Neutral	₹12.62B	38.83	―	2.63%	-10.71%	-40.89%
ASTEC	46 Neutral	₹18.75B	―	―	―	1.54%	-8.04%
HERANBA	44 Neutral	₹11.82B	385.17	―	0.39%	―	―

Astec Lifesciences Limited Corporate Events

Astec LifeSciences Announces Senior Management Change

Astec LifeSciences Limited, a company involved in the life sciences sector, has announced the resignation of Mr. Vivek Ramchandra Thorat from his position as Associate Vice President – Operations, effective from the close of working hours on October 24, 2025. This change in senior management is due to Mr. Thorat’s decision to pursue opportunities outside the company. The company has accepted his resignation and relieved him of his duties.

Astec LifeSciences Initiates Postal Ballot for Member Resolutions

Astec LifeSciences Limited has announced a Postal Ballot Notice to seek approval from its members for certain resolutions. The company is utilizing electronic means for voting, facilitated by the National Securities Depository Limited, and has made the necessary documents available on its website and other relevant platforms. This move is in compliance with regulatory requirements and reflects the company’s commitment to maintaining transparent communication with its stakeholders.

Astec LifeSciences Re-appoints Nandkumar Dhekne as Independent Director

Astec LifeSciences Limited, a company in the life sciences sector, has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting December 18, 2025, pending shareholder approval. Mr. Dhekne brings extensive experience in operations management and leadership in the Asia Pacific region, which is expected to bolster the company’s strategic direction and governance.

Astec LifeSciences Re-Appoints Key Independent Directors

Astec LifeSciences Limited has announced the re-appointment of Ms. Anjali Gupte and Mr. Nandkumar Dhekne as Non-Executive & Independent Directors for a second term of five years, starting from December 18, 2025, pending shareholder approval. This strategic move is expected to enhance the company’s governance and leverage Mr. Dhekne’s extensive experience in operations management and leadership across Asia Pacific, potentially strengthening Astec’s market position and operational efficiency.

Astec LifeSciences Re-appoints Nandkumar Dhekne as Independent Director

Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, to December 17, 2030, pending shareholder approval. This decision, approved by the Board of Directors based on the Nomination and Remuneration Committee’s recommendation, underscores the company’s commitment to maintaining experienced leadership. Mr. Dhekne brings extensive experience in operations management and leadership roles across Asia Pacific, which is likely to positively influence Astec’s strategic direction and stakeholder confidence.

Astec LifeSciences Re-Appoints Nandkumar Dhekne as Independent Director

Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, to December 17, 2030, pending shareholder approval. This decision, based on the Nomination and Remuneration Committee’s recommendation, highlights the company’s commitment to maintaining experienced leadership, as Mr. Dhekne brings extensive expertise in operations management and sales across the Asia Pacific region, which could positively impact the company’s strategic direction and stakeholder confidence.

Astec LifeSciences Re-appoints Nandkumar Dhekne as Independent Director

Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, subject to shareholder approval. This strategic move leverages Mr. Dhekne’s extensive experience in operations management and leadership across the Asia Pacific region, potentially strengthening the company’s governance and strategic direction.

Astec LifeSciences Re-appoints Nandkumar Dhekne as Independent Director

Astec LifeSciences Limited has announced the re-appointment of Mr. Nandkumar Dhekne as a Non-Executive & Independent Director for a second term of five years, starting from December 18, 2025, to December 17, 2030, pending shareholder approval. Mr. Dhekne brings extensive experience in field services, operations management, and sales, having held senior leadership roles across the Asia Pacific region, which is expected to bolster Astec’s strategic direction and governance.